News
Kamada presents study on inhaled AAT in cystic fibrosis at European Respiratory Society congress
Business Wire
NESS ZIONA, Israel—The Israeli bio-pharmaceutical company Kamada announced that data from a clinical study on its inhaled alpha-1 antitrypsin protein (AAT) in cystic fibrosis patients was presented today at the annual congress of the European Respiratory Society (ERS) in Vienna, Austria. As previously reported, the study showed that inhaled AAT was safe and biologically effective.
David Tsur, Chief Executive Officer of Kamada said, “We are delighted that Kamada was invited to present the results of its Phase II clinical study with inhaled-AAT at the European Respiratory Society meeting at a session focused on novel therapies for cystic fibrosis”.
